Hyaluronic acid concentration in liver diseases.
The aim of this study was to evaluate the effect of liver diseases of different etiologies and clinical severity of liver cirrhosis on the serum level of hyaluronic acid. The results were compared with noninvasive markers of liver fibrosis: APRI, GAPRI, HAPRI, FIB-4 and Forn's index. Serum samples were obtained from 20 healthy volunteers and patients suffering from alcoholic cirrhosis (AC)-57 patients, non-alcoholic cirrhosis (NAC)-30 and toxic hepatitis (HT)-22. Cirrhotic patients were classified according to Child-Pugh score. Hyaluronic acid concentration was measured by the immunochemical method. Non-patented indicators were calculated using special formulas. The mean serum hyaluronic acid concentration was significantly higher in AC, NAC and HT group in comparison with the control group. There were significant differences in the serum hyaluronic acid levels between liver diseases, and in AC they were significantly higher than those in NAC and HT group. The serum hyaluronic acid level differs significantly due to the severity of cirrhosis and was the highest in Child-Pugh class C. The sensitivity, specificity, accuracy, positive and negative predictive values and the area under the ROC curve for hyaluronic acid and all non-patented algorithms were high and similar to each other. We conclude that the concentration of hyaluronic acid changes in liver diseases and is affected by the severity of liver cirrhosis. Serum hyaluronic acid should be considered as a good marker for noninvasive diagnosis of liver damage, but the combination of markers is more useful.
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269, Białystok, Poland.
Monika
M
Gudowska
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269, Białystok, Poland.
Ewa
E
Gruszewska
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St., 15-540, Białystok, Poland.
Anatol
A
Panasiuk
Department of Pediatric Laboratory Diagnostics, Medical University of Bialystok, Waszyngtona 17 St., 15-269, Białystok, Poland.
Bogdan
B
Cylwik
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St., 15-540, Białystok, Poland.
Robert
R
Flisiak
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St., 15-540, Białystok, Poland.
Magdalena
M
Świderska
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269, Białystok, Poland.
Maciej
M
Szmitkowski
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269, Białystok, Poland. chrostek@umb.edu.pl.
Lech
L
Chrostek
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood*; D008103:Liver Cirrhosis / Q000097:blood / Q000473:pathology; D008107:Liver Diseases / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012720:Severity of Illness Index
D015415:Biomarkers; D006820:Hyaluronic Acid
Hyaluronic acid; Liver cirrhosis; Liver fibrosis; Toxic hepatitis